115 related articles for article (PubMed ID: 12152158)
21. E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity.
Zhou Z; Guan H; Kleinerman ES
Mol Cancer Res; 2005 May; 3(5):271-5. PubMed ID: 15886298
[TBL] [Abstract][Full Text] [Related]
22. Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival.
Tomicic MT; Christmann M; Kaina B
Cancer Res; 2005 Oct; 65(19):8920-6. PubMed ID: 16204064
[TBL] [Abstract][Full Text] [Related]
23. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
[TBL] [Abstract][Full Text] [Related]
24. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
Giaccone G; van Ark-Otte J; Scagliotti G; Capranico G; van der Valk P; Rubio G; Dalesio O; Lopez R; Zunino F; Walboomers J
Biochim Biophys Acta; 1995 Dec; 1264(3):337-46. PubMed ID: 8547322
[TBL] [Abstract][Full Text] [Related]
25. Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa.
Hirata S; Katoh O; Oguri T; Watanabe H; Yajin K
Jpn J Cancer Res; 2000 Jan; 91(1):84-90. PubMed ID: 10744048
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas.
Holden JA; Perkins SL; Snow GW; Kjeldsberg CR
Am J Clin Pathol; 1995 Jul; 104(1):54-9. PubMed ID: 7611182
[TBL] [Abstract][Full Text] [Related]
27. DNA topoisomerase I and IIalpha expression in penile carcinomas: assessing potential tumour chemosensitivity.
Berney DM; Stankiewicz E; Adlan AM; Kudahetti S; Biedrzycki OJ; Hadway P; Watkin N; Corbishley C
BJU Int; 2008 Sep; 102(8):1040-4. PubMed ID: 18489530
[TBL] [Abstract][Full Text] [Related]
28. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone.
Harker WG; Slade DL; Parr RL; Holguin MH
Cancer Res; 1995 Nov; 55(21):4962-71. PubMed ID: 7585537
[TBL] [Abstract][Full Text] [Related]
29. Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Yoshida M
Anticancer Res; 2001; 21(2A):905-10. PubMed ID: 11396183
[TBL] [Abstract][Full Text] [Related]
30. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
[TBL] [Abstract][Full Text] [Related]
31. Elevations of DNA topoisomerase I in invasive carcinoma of the breast.
Lynch BJ; Bronstein IB; Holden JA
Breast J; 2001; 7(3):176-80. PubMed ID: 11469931
[TBL] [Abstract][Full Text] [Related]
32. DNA topoisomerase IIalpha in multiple myeloma: a marker of cell proliferation and not drug resistance.
Wilson CS; Medeiros LJ; Lai R; Butch AW; McCourty A; Kelly K; Brynes RK
Mod Pathol; 2001 Sep; 14(9):886-91. PubMed ID: 11557785
[TBL] [Abstract][Full Text] [Related]
33. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
[TBL] [Abstract][Full Text] [Related]
34. Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers.
Kim R; Ohi Y; Inoue H; Toge T
Anticancer Res; 1999; 19(6B):5393-8. PubMed ID: 10697567
[TBL] [Abstract][Full Text] [Related]
35. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer.
Nakopoulou L; Lazaris AC; Kavantzas N; Alexandrou P; Athanassiadou P; Keramopoulos A; Davaris P
Pathobiology; 2000; 68(3):137-43. PubMed ID: 11174071
[TBL] [Abstract][Full Text] [Related]
36. Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins.
Taniguchi K; Kohno K; Kawanami K; Wada M; Kanematsu T; Kuwano M
Cancer Res; 1996 May; 56(10):2348-54. PubMed ID: 8625310
[TBL] [Abstract][Full Text] [Related]
37. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
38. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
[TBL] [Abstract][Full Text] [Related]
39. Human DNA topoisomerase II-alpha.
Martinchick J; Rahn M; Jolles C; Holden J
Int J Oncol; 1997 Jun; 10(6):1229-34. PubMed ID: 21533509
[TBL] [Abstract][Full Text] [Related]
40. [Immunohistochemical evaluation of intracranial recurrent meningiomas: correlation of topoisomerase II alpha expression and cell proliferative potential].
Tanaka M; Kubo O; Tajika Y; Takahashi T; Suzuki S; Takakura K
No To Shinkei; 1999 Dec; 51(12):1033-9. PubMed ID: 10654298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
